Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immun... by Mahant, A, Saubi, N, Eto, Y, Guitart, N, Gatell, J, Hanke, T, Joseph, J

Engineering New E.coli-Mycobacterial Shuttle Vector for a Dual HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG by Saubi, N, Gea-Mallorqui, E, Hurtado, C, Hanke, T, Ferrer, P, Gatell, J, Joseph, J

Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine by Saubi N, Gea-Mallorquí E, Mbewe-Mvula A, Hurtado C, Gatell J, Hanke T, Joseph J

Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG by Saubi, N, Mbewe-Mvula, A, Gea-Mallorqui, E, Rosario, M, Gatell, J, Hanke, T, Joseph, J

Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine by Saubi, N, Gea-Mallorqui, E, Mbewe-Mvula, A, Hurtado, C, Gatell, J, Hanke, T, Joseph, J

P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes by Hanke T, Gatell J, Cardona P, Gil O, Fernandez-Lloris R, Im E, Saubi N, Joseph J

Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes. by Saubi, N, Im, E, Fernández-Lloris, R, Gil, O, Cardona, P, Gatell, J, Hanke, T, Joseph, J

Newborn Mice Vaccination with BCG.HIVA(222) plus MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes by Saubi, N, Im, E, Fernandez-Lloris, R, Gil, O, Cardona, P, Gatell, J, Hanke, T, Joseph, J

Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. by Im, E, Saubi, N, Virgili, G, Sander, C, Teoh, D, Gatell, J, Mcshane, H, Joseph, J, Hanke, T

P10-13. Increased production of alpha-defensins 1–3 by dendritic cells in HIV-infected individuals is associated with a slower disease progression rate by Gatell J, Leon A, Miralles L, Rovira C, Oliva H, Climent N, Rodriguez-Garcia M, Garcia F, Gallart T

Cellular immune responses and changes in VL after a Dendritic Cells (DC)-based therapeutic vaccine in cART treated chronic HIV-infected patients with CD4 T cells above 450/mm by García F, Guardo AC, Maleno M, Papagno L, Bargalló M, Climent N, Autran B, Gatell J, Gallart T, Plana M

Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment by Vidal, F, Mensa, J, Almela, M, Martinez, J, Marco, F, Casals, C, Gatell, J, Soriano, E, deAnta, M

Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. by Vidal, F, Mensa, J, Almela, M, Martínez, J, Marco, F, Casals, C, Gatell, J, Soriano, E, Jimenez de Anta, M

P20-06. Study of viral variability evolution in patients submitted to a therapeutic vaccine based on autologous dendritic cells pulsed with autologous HIV-1 by Gatell J, Gallart T, Miró J, Pumarola T, Hurtado C, García M, Climent N, Martinez-Picado J, García F, Dalmau J, Gil C, Guilà M

Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. by Plana, M, Garcia, F, Oxenius, A, Ortiz, G, Lopez, A, Cruceta, A, Mestre, G, Fumero, E, Fagard, C, Sambeat, M, Segura, F, Miró, J, Arnedo, M, Lopalcos, L, Pumarola, T, Hirschel, B, Phillips, R, Nixon, D, Gallart, T, Gatell, J

Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine by Ellefsen-Lavoie K, Rockstroh J, Pollard R, Pantaleo G, Podzamczer D, Asmuth D, van Lunzen J, Arastéh K, Schürmann D, Peters B, Clotet B, Hardy D, Lazzarin A, Gatell J, Sommerfelt MA, Baksaas I, Wendel-Hansen V, Sørensen B

A step ahead on the HIV collaboratory. by Murphy, R, Autran, B, Katlama, C, Brucker, G, Debre, P, Calvez, V, Clotet, B, Clumeck, N, Costagliola, D, Deeks, S, Dorrell, L, Gatell, J, Haase, A, Klein, M, Lazzarin, A, Mcmichael, A, Papagno, L, Schacker, T, Wain-Hobson, S, Walker, B, Youle, M

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. by Fagard, C, Oxenius, A, Günthard, H, Garcia, F, Le Braz, M, Mestre, G, Battegay, M, Furrer, H, Vernazza, P, Bernasconi, E, Telenti, A, Weber, R, Leduc, D, Yerly, S, Price, D, Dawson, S, Klimkait, T, Perneger, T, McLean, A, Clotet, B, Gatell, J, Perrin, L, Plana, M, Phillips, R, Hirschel, B

Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. Joint Concorde and Opal Coordinating Committee. by Aboulker, J, Babiker, A, Clumeck, N, Cooper, D, Darbyshire, J, Dormont, J, Gatell, J, Goebel, F, Laurian, Y, Mannucci, P, Mathiesen, L, Peto, T, Reiss, P, Sandstrom, E, Savidge, G, Seligmann, M, Smith, D, Stingl, G, Veenstra, J, Weller, I, Yeo, J, Lafon, E, McCormack, S, Swart, A, Withnall, R